National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.

Rapid Review

Commenced Completed Outcome
11/10/2013 31/10/2013 Full HTA not recommended